You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The past 6 years since the first edition of this book have seen great progress in the development of genetically engineered mouse (GEM) models of cancer. These models are finding an important role in furthering our understanding of the biology of malignant disease. A comfortable position for GEM models in the routine conduct of screening for potential new therapeutics is coming more slowly but is coming. Increasing numbers of genetically engineered mice are available, some with conditional activation of oncogenes, some with multiple genetic changes providing mouse models that are moving closer to the human disease.
Cancer is a group of different diseases (more than 100) characterised by uncontrolled growth and spread of abnormal cells. Cancer can arise in many sites and behave differently depending on its organ of origin. If a cancer spreads (metastasises), the new tumour bears the same name as the original (primary) tumour. Significant progress has been made in recent years in the battle against cancer and in understanding its underlying biological mechanisms. This research progress has resulted in many experimental treatments and cures. This book presents new and important research from around the world.
The chapters in this book are those presented at the Second International Symposium on Fundamental Problems in Breast Cancer held at Banff, Alberta, April 26-29, 1986. This is, therefore, the second volume in the series of symposia held in the Canadian Rockies. The aim of these symposia is to provide a supportive atmosphere for the development of new concepts as well as for the presentation of high quality scientific data. This is reflected in the chapters presented here. Many of the chapters put forward new hypotheses which will be tested in the clinic or laboratory in the next few years. In choosing the subjects for discourse, we preferred to tackle areas where controversy existed, and in ...
The first part of this book summarizes the rationale and the preclinical data for combined treatment with ionizing radiation and pharmaceutical agents. Individual chapters focus on forms of combined treatment, with due consideration being given to a range of drugs and to emerging combinations with small molecules and antibodies. The second part comprises a series of disease-specific chapters in which the clinical results of combined modality treatment are presented.
Radiation Oncology: Rationale, Technique, Results, by James D. Cox, MD and K. Kian Ang, MD, PhD, provides you with authoritative guidance on the latest methods for using radiotherapy to treat patients with cancer. Progressing from fundamental principles through specific treatment strategies for the cancers of each organ system, it also addresses the effects of radiation on normal structures and the avoidance of complications. This 9th edition covers the most recent indications and techniques in the field, including new developments in proton therapy and intensity-modulated radiotherapy (IMRT). It also features, for the first time, full-color images throughout the text to match those that you...
Although general morphological features have been used to consistently identify the changes in cell ultrastructure occurring during apoptosis, as distinct from necrosis, important advances have been achieved more recently in the investigation of the cellular and molecular aspects of this process. This book brings together the latest international research on the complex subject of programmed cell death, and covers such areas as the biochemical mechanisms, introduction of DNA fragmentation, enetic regulation, and the importance of apoptosis in the immune system, particularly during T-cell development, and in cancer. The comparison of a number of common signal transduction pathways with those involved in cell growth highlights an important relationship between apoptosis and the control of cell proliferation.
An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.
Advances in Cancer Research